Exon skipping mutations in neurofibromatosis

Methods in Molecular Biology

Volumn 867, Issue , 2012, Pages 65-76

  Buratti, Emanuele ^a   Baralle, Diana ^b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Exon skipping; Minigene systems; Neurofibromatosis; Neurofibromin; NF 1 gene; Pre mRNA splicing

Indexed keywords

RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ARTICLE; EXON; GENETIC TRANSFECTION; GENETICS; HUMAN; MUTATION; NEUROFIBROMATOSIS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; EXONS; GENES, NEUROFIBROMATOSIS 1; HUMANS; MUTATION; NEUROFIBROMATOSES; RNA PRECURSORS; TRANSFECTION;

EID: 84859872672     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-767-5_5     Document Type: Article

References (54)

1. Baralle D, Lucassen A, Buratti E (2009) Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep 10:810-816
2. Raponi M, Baralle D (2010) Alternative splicing: good and bad effects of translationally silent substitutions. FEBS J 277:836-840
3. Buratti E, Baralle M, Baralle FE (2006) Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 34:3494-3510
4. Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, Cooper DN (2007) Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28:150-158 (Pubitemid 46233312)
5. Vorechovsky I (2006) Aberrant 3 ¢ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 34:4630-4641 (Pubitemid 44590994)
6. Buratti E, Chivers M, Kralovicova J, Romano M, Baralle M, Krainer AR, Vorechovsky I (2007) Aberrant 5 ¢ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 35:4250-4263 (Pubitemid 47260233)
7. Roca X, Sachidanandam R, Krainer AR (2003) Intrinsic differences between authentic and cryptic 5 ¢ splice sites. Nucleic Acids Res 31:6321-6333 (Pubitemid 37442360)
8. Galante PA, Sakabe NJ, Kirschbaum-Slager N, de Souza SJ (2004) Detection and evaluation of intron retention events in the human transcriptome. RNA 10:757-765 (Pubitemid 38529738)
9. Dhir A, Buratti E (2010) Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies. FEBS J 277: 841-855
10. Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lazaro C, Estivill X (2000) Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet 9:237-247 (Pubitemid 30052747)
11. Teraoka SN, Telatar M, Becker-Catania S, Liang T, Onengut S, Tolun A, Chessa L, Sanal O, Bernatowska E, Gatti RA, Concannon P (1999) Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet 64:1617-1631 (Pubitemid 30481513)
12. Stenson PD, Ball EV, Howells K, Phillips AD, Mort M, Cooper DN (2009) The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum Genomics 4:69-72
13. Pros E, Gomez C, Martin T, Fabregas P, Serra E, Lazaro C (2008) Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat 29:E173-E193
14. Wimmer K, Roca X, Beiglbock H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L (2007) Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5 ¢ splice-site disruption. Hum Mutat 28:599-612 (Pubitemid 46744290)
15. Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lazaro C (2003) Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 40:e82
16. Bernards A (1995) Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta 1242:43-59
17. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatrics 123:124-133
18. Trovo-Marqui AB, Tajara EH (2006) Neurofibromin: a general outlook. Clin Genet 70:1-13 (Pubitemid 44192729)
19. Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593-604 (Pubitemid 32201953)
20. Costa RM, Silva AJ (2002) Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol 17:622-626, discussion 627-629, 646-651 (Pubitemid 35203624)
21. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA et al (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192
22. Gutmann DH, Zhang Y, Hirbe A (1999) Developmental regulation of a neuron-specific neurofi-bromatosis 1 isoform. Ann Neurol 46:777-782 (Pubitemid 29518141)
23. Gutmann DH, Geist RT, Rose K, Wright DE (1995) Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn 202: 302-311
24. Danglot G, Regnier V, Fauvet D, Vassal G, Kujas M, Bernheim A (1995) Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5 ¢ part of the gene. Hum Mol Genet 4:915-920
25. Gutmann DH, Andersen LB, Cole JL, Swaroop M, Collins FS (1993) An alternatively-spliced mRNA in the carboxy terminus of the neurofi-bromatosis type 1 (NF1) gene is expressed in muscle. Hum Mol Genet 2:989-992 (Pubitemid 23216632)
26. Andersen LB, Ballester R, Marchuk DA, Chang E, Gutmann DH, Saulino AM, Camonis J, Wigler M, Collins FS (1993) A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 13:487-495 (Pubitemid 23006926)
27. Zhu H, Hinman MN, Hasman RA, Mehta P, Lou H (2008) Regulation of neuron-specific alternative splicing of neurofibromatosis type 1 pre-mRNA. Mol Cell Biol 28:1240-1251 (Pubitemid 351214127)
28. Barron VA, Zhu H, Hinman MN, Ladd AN, Lou H (2010) The neurofibromatosis type I pre-mRNA is a novel target of CELF proteinmediated splicing regulation. Nucleic Acids Res 38:253-264
29. Park VM, Kenwright KA, Sturtevant DB, Pivnick EK (1998) Alternative splicing of exons 29 and 30 in the neurofibromatosis type 1 gene. Hum Genet 103:382-385 (Pubitemid 28542944)
30. Vandenbroucke I, Callens T, De Paepe A, Messiaen L (2002) Complex splicing pattern generates great diversity in human NF1 transcripts. BMC Genomics 3:13
31. Vandenbroucke I, Vandesompele J, De Paepe A, Messiaen L (2002) Quantification of NF1 transcripts reveals novel highly expressed splice variants. FEBS Lett 522:71-76 (Pubitemid 34722500)
32. Thomson SA, Wallace MR (2002) RT-PCR splicing analysis of the NF1 open reading frame. Hum Genet 110:495-502 (Pubitemid 36074996)
33. Buratti E, Baralle M, De Conti L, Baralle D, Romano M, Ayala YM, Baralle FE (2004) hnRNP H binding at the 5 ¢ splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes. Nucleic Acids Res 32:4224-4236 (Pubitemid 39232295)
34. Baralle M, Skoko N, Knezevich A, De Conti L, Motti D, Bhuvanagiri M, Baralle D, Buratti E, Baralle FE (2006) NF1 mRNA biogenesis: effect of the genomic milieu in splicing regulation of the NF1 exon 37 region. FEBS Lett 580:4449-4456 (Pubitemid 44118266)
35. Raponi M, Buratti E, Dassie E, Upadhyaya M, Baralle D (2009) Low U1 snRNP dependence at the NF1 exon 29 donor splice site. FEBS J 276:2060-2073
36. Raponi M, Upadhyaya M, Baralle D (2006) Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization. Hum Mutat 27:294-295
37. Raponi M, Buratti E, Llorian M, Stuani C, Smith CW, Baralle D (2008) Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1. FEBS J 275:6101-6108
38. Aartsma-Rus A, van Ommen GJ (2007) Antisensemediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609-1624 (Pubitemid 47481669)
39. Garcia-Blanco MA (2005) Making antisense of splicing. Curr Opin Mol Ther 7:476-482 (Pubitemid 41489189)
40. Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta 1792:14-26
41. Pros E, Fernandez-Rodriguez J, Canet B, Benito L, Sanchez A, Benavides A, Ramos FJ, Lopez-Ariztegui MA, Capella G, Blanco I, Serra E, Lazaro C (2009) Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat 30:454-462
42. Pros E, Fernandez-Rodriguez J, Benito L, Ravella A, Capella G, Blanco I, Serra E, Lazaro C (2010) Modulation of aberrant NF1 premRNA splicing by kinetin treatment. Eur J Hum Genet 18:614-617
43. Vibe-Pedersen K, Kornblihtt AR, Baralle FE (1984) Expression of a human alpha-globin/fibronectin gene hybrid generates two mRNAs by alternative splicing. EMBO J 3:2511-2516
44. Baralle D, Baralle M (2005) Splicing in action: assessing disease causing sequence changes. J Med Genet 42:737-748 (Pubitemid 41475248)
45. Cooper TA (2005) Use of minigene systems to dissect alternative splicing elements. Methods 37:331-340 (Pubitemid 41682503)
46. Singh G, Cooper TA (2006) Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques 41:177-181 (Pubitemid 46542601)
47. Orengo JP, Bundman D, Cooper TA (2006) A bichromatic fl uorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res 34:e148
48. Bonano VI, Oltean S, Brazas RM, Garcia-Blanco MA (2006) Imaging the alternative silencing of FGFR2 exon IIIb in vivo. RNA 12:2073-2079 (Pubitemid 44865955)
49. Bonano VI, Oltean S, Garcia-Blanco MA (2007) A protocol for imaging alternative splicing regulation in vivo using fl uorescence reporters in transgenic mice. Nat Protoc 2:2166-2181 (Pubitemid 351565855)
50. Newman EA, Muh SJ, Hovhannisyan RH, Warzecha CC, Jones RB, McKeehan WL, Carstens RP (2006) Identification of RNA-binding proteins that regulate FGFR2 splicing through the use of sensitive and specific dual color fl uorescence minigene assays. RNA 12:1129-1141 (Pubitemid 43788130)
51. Nasim MT, Chowdhury HM, Eperon IC (2002) A double reporter assay for detecting changes in the ratio of spliced and unspliced mRNA in mammalian cells. Nucleic Acids Res 30:e109
52. Kishore S, Khanna A, Stamm S (2008) Rapid generation of splicing reporters with pSpliceExpress. Gene 427:104-110
53. Pros E, Larriba S, Lopez E, Ravella A, Gili ML, Kruyer H, Valls J, Serra E, Lazaro C (2006) NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing. Hum Mutat 27:1104-1114 (Pubitemid 44730505)
54. Skoko N, Baralle M, Buratti E, Baralle FE (2008) The pathological splicing mutation c.6792C > G in NF1 exon 37 causes a change of tenancy between antagonistic splicing factors. FEBS Lett 582:2231-2236